Tradestie Institutional Equity Comparison Engine

OBIO vs MNOV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MNOV Overall Edge

MNOV Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Medicinova, Inc. (MNOV) driven by superior Valuation, Growth & Margin while OBIO counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, OBIO trades at N/M Forward P/E with -195.4% operating margin (-89.4% YoY revenue) versus MNOV at 8.5x Forward P/E and -1232.2% operating margin (+12.4% YoY). In options structure, OBIO sits in CONSOLIDATION (21st %ile IV; Dealer Gamma Walls on Pro) against MNOV sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MNOV
OBIO N/M vs MNOV 8.5x Fwd P/E
Growth & Margin Winner MNOV
Op Margin -195.4% vs -1232.2% ยท YoY -89.4% vs +12.4%
Momentum & Technical Winner OBIO
1Y +41.2% vs -8.4% ยท 52W Pos 72% vs 3%
Options & Structure Winner OBIO
CONSOLIDATION (21st %ile IV) vs UNCLASSIFIED (50th %ile IV)
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.58
-6.0% 1D
Market Cap $550.9M
1M Return +20.29%
1Y Return +41.2%
Forward P/E N/M
Unified AI Score
41.1 / 100 SELL
Tech 15.0 Fund 36.0 Flow 64.0 Mom 40.0
MNOV NASDAQ
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
1M Return -7.09%
1Y Return -8.39%
Forward P/E 8.5x
Unified AI Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: OBIO +41.2% MNOV -8.39% Spread: +49.59 pp (OBIO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period OBIO Revenue MNOV Revenue OBIO Op. Margin MNOV Op. Margin Margin Edge
FY2012 N/A $0M N/A -1363.8% MNOV
FY2021 N/A $0M N/A -253.0% MNOV
FY2022 $0M N/A -924.3% N/A OBIO
FY2023 $0M $0M -1866.2% -990.0% MNOV
FY2024 $0M N/A -2437.5% N/A OBIO
FY2025 $30M $0M -154.7% -3242.5% OBIO

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: OBIO (3) vs MNOV (7)
Institutional Metric OBIO MNOV Criterion Row Winner
Market Capitalization Scale $550.9M $65.1M Larger Scale OBIO
Trailing P/E Ratio Valuation N/M 8.5x Lower Multiple MNOV
Forward P/E Ratio Valuation N/M 8.5x Lower Multiple MNOV
Revenue Growth (YoY) Growth -89.4% +12.4% Higher Growth MNOV
Operating Margin (TTM) Profitability -195.4% -1232.2% Higher Margin OBIO
Net Profit Margin Profitability -182.5% 0.0% Higher Margin MNOV
Return on Equity (ROE) Capital Efficiency -182.3% -24.8% Higher ROE MNOV
52-Week Range Position Momentum 72% ($3โ€“$8) 3% ($1โ€“$4) Stronger Trend OBIO
Beta / 30D Volatility Risk Regime 1.18ฮฒ ยท 88% Vol 0.59ฮฒ ยท 38% Vol Lower Realized Risk MNOV
Unified Institutional Score Composite Signal 41.1 / 100 (SELL) 50.2 / 100 (HOLD) Higher Composite MNOV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full OBIO vs MNOV Buy Guide
OBIO CONSOLIDATION
36d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 21st %ile
IV Regime Compressed (<25th %ile)
Live OBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MNOV UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MNOV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither OBIO nor MNOV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.